ADAPT AF-DES Trial (2025) Therapy for Atrial Fibrillation in Patients with Drug-Eluting StentsMulticenter, randomized, open-label, noninferiority trial Objective:In patients with atrial fibrillation (AF) who previously underwent drug-eluting stent (DES) implantation, does NOAC monotherapy provide similar protection against ischemic and bleeding … Read More
afib
ASSET-IT Trial: Early Tirofiban Infusion in Stroke
The 2025 ASSET-IT trial investigated whether early intravenous infusion of tirofiban, an antiplatelet agent, following intravenous thrombolysis could improve outcomes in patients with acute noncardioembolic ischemic stroke who are not eligible for thrombectomy. This phase 3, double-blind, randomized, placebo-controlled study … Read More
PROMPT-AF Trial: PVI With Optimized Linear Ablation for Persistent AFib
Understanding the PROMPT-AF Trial: A Breakthrough in Persistent AF Management The PROMPT-AF trial marks an important step forward in our understanding of how to manage persistent atrial fibrillation (AF) more effectively. Conducted as an investigator-initiated, multicenter, open-label randomized trial, PROMPT-AF … Read More
ARTESIA Trial: Apixaban for Subclinical AFib
ARTESIA Trial Summary The ARTESIA trial, which stands for “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation,” was a landmark study aimed at comparing the efficacy and safety of apixaban versus aspirin in patients with subclinical atrial fibrillation (AF). The … Read More
CASTLE HTx Trial: Ablation in HF and AFib
The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More
ADVENT Trial: Pulse Field Ablation for AFib
The ADVENT trial, published in the New England Journal of Medicine in 2023, was a randomized, single-blind, noninferiority trial designed to compare the safety and efficacy of pulsed field ablation with conventional thermal ablation techniques (radiofrequency or cryoballoon) for the … Read More
ELAN Trial: Early vs. Later Initiation of DOAC in Acute Ischemic Stroke and Atrial Fibrillation
ELAN Trial Summary Introduction:The ELAN trial aimed to investigate the optimal timing of initiating direct oral anticoagulants (DOACs) in individuals with atrial fibrillation (AF) who had experienced an acute ischemic stroke. The study compared early anticoagulation (initiated within 48 hours … Read More
Navigating the New Era: Landmark Clinical Trials on Eliquis (Apixaban) for Anticoagulation in Atrial Fibrillation
Atrial fibrillation (AFib) is a prevalent cardiac arrhythmia that significantly elevates the risk of stroke and systemic embolism. As a result, effective anticoagulation therapy is crucial for managing AFib patients. Over the past decade, novel oral anticoagulants (NOACs) have challenged … Read More
Pioneering the Path: Key Landmark Trials on Ablation Procedures for Atrial Fibrillation
Delve into the pivotal clinical trials that have shaped our understanding and management of atrial fibrillation through ablation procedures. … Read More
APAF Trial: Ablation or Antiarrhythmics for PAF
2006 APAF STUDY A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation (AF) randomized controlled trial M Objective: To compare the relative efficacy of circumferential pulmonary vein ablation (CPVA) & antiarrhythmic drug … Read More